Jayson Bedford

Conceded leverage ran ahead of plan and flagged the offsetting Ireland hiring and depreciation in Q3 rather than claiming the Q2 rate is the run rate.

Jake confirmed Smart Basal still in pilot with updates made based on clinical workflow learnings. Algorithm not being revalidated; focus is on workflow integration across large diabetes clinics and small primary care offices. Plans to expand throughout the year with big launch once workflow finalized.

Jake confirmed Smart Basal as key tool for basal segment growth. Piloting at selected US clinics this month to learn workflows and integration. Designed to pair G7 with personalized dosing to get patients to optimal dose faster with no hypoglycemia.

Jake provided detailed utilization hierarchy: AID >90%, intensive insulin non-AID >85%, basal 80-85%, non-insulin T2 around 75%. MOBILE study showed 95% of patients wanted to continue CGM after trial. Stelo T2 non-insulin users highest utilization group on that platform.

Jereme confirmed 2-3% Stelo revenue guide unchanged. Kevin noted user mix shifting as G7 coverage expands: biggest group now health and wellness, then prediabetes, then T2 non-intensive. Amazon and Oura partnerships key to reaching broader population.

Jereme noted France and Japan as strength pockets. Some expected coverage wins slid in timing. Underlying volume demand strong; some choppiness in international as coverage wins land.

Jereme confirmed Stello 2-3% guidance unchanged. T2 coverage already effective Jan 1. Amazon launch expected Q1. Jake noted Oura integration coming H1 2025.

Schmid described a broadening Middle East disruption and called it short term but gave no dollar impact.

Schmid cited wound closure, biosurgery and endomechanical innovation plus OTTAVA, without detailing specific international actions.

Tim Schmid framed the slowdown as behavioral post the neutral U.K. trial and pointed to PROTECT IV in 2027, but gave no specific new growth number.

Wolk characterized the reserve adjustment as moderate but not material to overall MedTech performance.

Flavia explained international price/mix realization will continue positive but at more moderate pace as company anniversaries successful launches and DASH-to-Omnipod 5 conversion progresses. Dollars will continue increasing sequentially on constant currency basis but growth rate will decelerate. Did not directly address whether Q1 had stocking impact.

Ana confirmed international Omnipod 5 conversions reached 50% of total base, up from 40% last quarter. Price/mix realization in low double digits this quarter. Majority of OUS growth from three core markets (UK, France, Germany). New market launches (Italy, Nordics, Australia, Belgium, Switzerland, Canada) have not had material impact yet.

Jim emphasized strategic imperative to grow both but did not confirm specific type 1 vs type 2 splits in guidance. Noted Insulet is clear market leader in both NCS overall and type 1.

Hider declined to confirm or deny refiling but said corrections will be implemented in coordination with regulatory authorities including any necessary submissions. Ship hold assumed for full year. Pleased with team progress on finalizing hardware and software corrections.

Anita Zielinski confirmed Q1 returns were not material, consistent with improving trend. Full-year guidance continues to factor in the possibility of returns with ship hold assumed throughout 2026.

Tom confirmed Alaris share nearing 60%. Strong competitive funnel going forward. New 510(k) submissions planned for late this year adding features to current platform. Whole new Alaris platform moving forward through innovation pipeline.

Mahoney put WAMGR at 7% to 8%, a tick down of about 1 point, and noted WATCHMAN is under 10% of revenue; on Urology he guided to flat to maybe up 1% for the full year.